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ABSTRACT
ITRACONAZOLE NANOCOMPOSITES PREPARED VIA ROTARY
EVAPORATOR DRYING OF NANOMILLED SUSPENSIONS
by
Alexander Santos Coelho
The aim of this study is to explore the feasibility of rotary evaporation for drying wetmilled drug suspensions as a novel approach to produce drug nanocomposites that exhibit
fast redispersion and immediate drug release. To this end, the physical stability of the
nanomilled itraconazole (drug) suspensions, a.k.a., nanosuspensions, during the milling
and storage; the drying of the itraconazole nanosuspensions via the rotary evaporator; and
the type/loading of various polymers/surfactants (dispersants) on aqueous redispersion and
drug release from the nanocomposites were examined. Our results suggest that smaller
drug particle size, owing to nanomilling, and smaller nanocomposite particle size, owing
to optimized drying and subsequent mortar–pestle milling, as well as higher concentration
of hydrophilic polymers/surfactants enhanced redispersion and drug release. Overall,
rotary evaporation of drug nanosuspensions could achieve fast redispersion and immediate
release of poorly soluble drugs from these nanocomposites, with less concern over potential
flowability issues than spray-dried nanocomposites.
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CHAPTER 1
INTRODUCTION

1.1 Motivation
In the pipeline a large percentage, about 40%, of newly developed drugs fall under poorly
water-soluble due to high molecular weight and hydrophobicity (Lipinski, 2002). Due to
their poor water solubility, a slow dissolution can lead to low bioavailability, which is not
conducive to developing effective therapeutic medicines (Fasano, 1998). Widely used
methods of combating the slow dissolution rates of these drugs include the implementation
of nanoparticle formation, amorphous solid dispersions, changing active particle surface
properties, and co-crystals (Anagha Bhakay et al., 2014; Jeong & Park, 2008; Niwa &
Danjo, 2013; Serajuddin, 1999; Yadav et al., 2009). These strategies all focused on the
enhancement of bioavailability through the manipulation of the drug particle size/surface
area or its solid-state. Most notably, the use of nanoparticles generated through wet stirred
media milling in the form of nanosuspensions has continued to be a reliable method of
increasing the drug dissolution rate to this day with approved FDA drugs (Malamatari et
al., 2018). However, as solid dosage forms such as tablets, capsules, etc. are preferred by
patients over liquid dosage forms due the convenience of the former, drug nanosuspensions
must be dried into nanocomposite powder prior to their incorporation into the solid
dosages. To dry these nanoparticle suspensions, techniques such as spray drying (Anagha
Bhakay et al., 2014; Bilgili et al., 2018; Rahman et al., 2019), fluidized bed coating
(Anagha Bhakay et al., 2014; Chaubal & Popescu, 2008; Vogt et al., 2008), and
lyophilization (Kim & Lee, 2010; Tuomela et al., 2015) have been widely used. All
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methods aim at evaporation of a solvent from the suspension leaving behind a solid
composite. A rotary evaporator that can apply vacuum and heating to a suspension has not
been used to prepare nanocomposites from wet media milled drugs before, which is in the
scope of this thesis work.
1.1.1 Drug Nanosuspensions
Within the literature, drug nanosuspensions have been a focal point to enhancing the
bioavailability of poorly water-soluble drugs (Bhakay, Rahman, et al., 2018). In the
pharmaceutical nanotechnology literature, drug nanosuspensions refer to aqueous solution
of various dispersants in which insoluble colloidal and truly nanosized particles all having
the particle size of less than 1µm in size are suspended. The dispersants such as polymers
and surfactants dissolve in water and provide physical stability to the nanocrystals by
preventing their aggregation (Junghanns & Muller, 2008). The desire to generate a
nanosuspension comes from the dissolution enhancement stemming from the larger surface
area of milled particles (Bhakay, Rahman, et al., 2018). The most common and widely used
method of milling a suspension is wet stirred media milling (Bhakay, Rahman, et al., 2018;
Malamatari et al., 2018; Schenck et al., 2019). This can be seen in Table 1.1 of FDA
approved drugs produced by wet stirred media milling. The technique for particle size
reduction is beneficial in its ability to have a continuous stirred process that can be cooled
with the assistance of a jacket for sensitive drug compounds compared to that of other
techniques (i.e. LabRAM milling) (Bilgili et al., 2018; Li, Zhang, et al., 2016). The wet
media milling can be setup in batch mode or in continuous recirculation mode in which the
suspension recirculated through the media chamber filled with beads facilitating the
breakage of suspended drug particles and a holding tank (A. Bhakay et al., 2014).
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Soluble polymers have been widely used as stabilizers in drug nanosuspensions and
film formers in drug nanocomposites (Bhakay, Rahman, et al., 2018; Li, Lopez, et al.,
2016). The polymer’s molecular weight, its adsorption onto drug surfaces, and viscosity
could have an impact on the extent of aggregation in drug nanosuspensions (Bilgili et al.,
2018; Choi et al., 2008). This impact will also show upon redispersion of nanocomposites
in various liquids once nanocomposites are formed (Bhakay et al., 2013). In addition,
surfactants could enhance physical stability of the drug nanosuspensions and wettability of
the nanocomposites, but its use could pose some challenges during storage (Li, Azad, et
al., 2016; Li, Lopez, et al., 2016; Müllertz et al., 2010). This is due to the micellar
solubilization of the drug nanoparticles which exists at higher concentrations and leads to
Ostwald ripening (Ghosh et al., 2011; Verma et al., 2011). Although the benefits of
surfactant use in formulations are present, its use should be minimized to reduce the
instability during long term storage and the Ostwald ripening which could occur during
storage and processing of composites.
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Table 1.1 Media Milled FDA Approved Drugs
Trade
name

Particle Size
Company

Reduction

Route

Method

Dosage

Year

Form

approved

King Pharma

Morphine sulfate

Pain medication

WMM

Oral

Capsule

2002

Emenda

Merck

Aprepitant

Antiemetic

WMM

Oral

Capsule

2003

ADHD

WMM

Oral

Capsule

2001

Appetite stimulant

WMM

Oral

Suspension

2005

Immunosuppressant

WMM

Oral

XRb

Novartis

Dexmethylphenidate
HCl

Par

ESa

Pharmaceutical

Rapamunea

Wyeth

Ritalin Lab

Novartis

Methylphenidate HCl

ADHD

WMM

Oral

Capsule

2002

Tricora

Abbott

Fenofibrate

Hypercholesterolemia

WMM

Oral

Tablet

2004

Zanaflexb

Acorda

Tizanidine HCl

Muscle relaxant

WMM

Oral

Capsule

2002

4

Megace

Based on (Verma & Burgess, 2009).
Based on (Shegokar & Müller, 2010).

b

Indication

Avinzab
Focalin

a

Active substance

Megestrol acetate
Sirolimus
(rapamycin)

Suspension,
Tablet

2000

1.1.2 Drug Nanocomposites
Despite the simplicity of generating a nanosuspension, generating a nanocomposite
becomes a much more difficult task. The milled nanoparticles within the suspension will
tend to aggregate if they are not stabilized with the appropriate dispersants either
immediately, after milling, or during storage (Li, Zhang, et al., 2016). This is due to the
Brownian motion that will cause nearby particles to aggregate together within a suspension
(Lee, 2003). These forces are typically at play when the suspension is in storage, where
nanoparticles could settle and collide with one another leading to aggregation dictated by
van der Waals forces (Napper, 1970). Additional phenomena such as Ostwald ripening
could also occur when the differences in drug solubility of differently sized particles could
cause the dissolved drug to deposit onto larger drug particles causing growth over time
(Verma et al., 2011). Due to these competing forces during the storage of the suspension,
the importance of stabilizing dispersants and the proper downstream processing are
required. As importantly, oral solid dosage forms of a drug are a preferred delivery over
that of suspensions. That requires the wet media milled nanosuspensions to be dried into
composites which will ultimately be used within a solid dosage unit. This can be performed
using spray drying (Anagha Bhakay et al., 2014; Bilgili et al., 2018; Rahman et al., 2019),
fluidized bed coating (Anagha Bhakay et al., 2014; Chaubal & Popescu, 2008; Vogt et al.,
2008), spray-freeze drying (Niwa & Danjo, 2013), freeze drying (Kim & Lee, 2010;
Tuomela et al., 2015) and vacuum drying (Choi et al., 2008; Kim & Lee, 2010). Each
drying method has its own pros/cons and poses unique challenges when generating drug
nanocomposites.
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Furthermore, it should be mentioned that not only do the dispersants affect physical
stability of the nanosuspensions, but also they affect the redispersibility of the
nanocomposites and drug release from them when they are dissolved in vivo or in vitro (A.
Bhakay et al., 2014; Bhakay et al., 2013; Bilgili et al., 2018; Li, Lopez, et al., 2016). The
redispersibility of drug nanocomposites, referring to their ability to release drug
nanoparticles, could be an important metric in the development of drug nanocomposites
(Bhakay et al., 2013; Bilgili et al., 2018) besides the widely used dissolution tests. It is
hypothesized that nanocomposite particle size and type/loading of the dispersants could
affect the redispersion as well as drug release during in vitro dissolution tests. This led to
the investigation of different polymer and surfactant combinations to discover the impact
on nanoparticle recovery (Bhakay et al., 2013).

1.2 Background and Challenges
1.2.1 Impact of Dispersants on Nanosuspension Stability
Although nanoparticle suspensions from wet media milling have shown to be effective in
dissolution enhancement of poorly water-soluble drugs (Azad et al., 2016; Anagha Bhakay
et al., 2014; Bilgili et al., 2018; Norbert Rasenack, 2002), aggregation and physical stability
need to be addressed for a proper nanosuspension to be made. To that end, dispersants such
as polymers, surfactants, sugars, and other stabilizers are used in nanosuspensions (Azad
et al., 2016; Anagha Bhakay et al., 2014; Bilgili et al., 2018; Choi et al., 2008; Ghosh et
al., 2011; Van Eerdenbrugh et al., 2008). Unfortunately, the concentration required to
achieve the desired stability can negatively affect the total drug concentration within a
given formulation leading to low drug formulations and larger tablet sizes (Bilgili et al.,
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2018). Furthermore, despite the required stability while as a suspension, during drying
aggregation can also occur compromising the composite and leading to poor redispersion
and dissolution (A. Bhakay et al., 2014; Bhakay, Rahman, et al., 2018).
One class of dispersants, surfactants, have been widely used throughout literature
to enhance drug wettability and provide electrostatic stabilization (Bhakay, Rahman, et al.,
2018; Bilgili et al., 2018; Li, Lopez, et al., 2016). Although they are great stabilizers they
are not without faults, in that suspensions with surfactants are susceptible to growth from
Ostwald ripening during milling and extended storage (Verma et al., 2011). To combat this
phenomenon, a combination of polymers and surfactants can be used to mitigate the issues
associated with a surfactant only formulation while retaining some beneficial properties of
a formulation containing a surfactant (Bilgili et al., 2018; Li, Lopez, et al., 2016; Müllertz
et al., 2010).
Another method of achieving a stable nanosuspension would be with the use of
surfactant-free formulations (Anagha Bhakay et al., 2014), where water soluble polymers
would make up the complete stability of the nanosuspension without the increased risk of
Ostwald ripening from surfactant. Examples of water-soluble polymers range from
hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), polyethylene glycol (PEG),
Kollidon VA 64 (VA 64), and Pluronic which have been used without the addition of
surfactants to stabilize nanosuspensions (Anagha Bhakay et al., 2014; Bilgili et al., 2018;
Fu et al., 2013). The addition of these polymers to stabilize nanosuspensions has been
studied by individuals using drying techniques such as spray drying (Bilgili et al., 2018),
fluidized bed coating (Anagha Bhakay et al., 2014), and freeze drying (Fu et al., 2013), but
none utilizing a rotary evaporator, which will require further investigation into the ability
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of polymers to stabilize the nanosuspension through the drying process as that poses a risk
to aggregated composites which will disperse and dissolve very poorly.
Itraconazole (ITZ), a model antifungal drug, has been used to model BCS Class II
drugs that have characteristic high permeability, but poor water solubility 0.002µg/ml
(Ghazal et al., 2009). Multiple research groups have investigated nanoparticle suspensions
of ITZ and their progression through a variety of drying studies including fluidized bed
coating, freeze drying, and spray drying, respectively (Azad et al., 2016; Badawi et al.,
2011; Bilgili et al., 2018). None has investigated the rotary evaporation of ITZ
nanosuspension which will bring its own challenges of suspension aggregation and method
development.
1.2.2 Comparison of Different Drying Methods
Drug nanosuspensions are precursors in the preparation of drug nanocomposites; they are
dried to form nanocomposites to be integrated into final solid dosage forms that are
preferred delivery route for therapeutics (Bhakay, Rahman, et al., 2018; Malamatari et al.,
2018; Shegokar & Müller, 2010; Verma & Burgess, 2009). As such, generating these
nanocomposites can be done using spray drying (Anagha Bhakay et al., 2014; Bilgili et al.,
2018; Rahman et al., 2019), fluidized bed coating (Anagha Bhakay et al., 2014; Chaubal
& Popescu, 2008; Vogt et al., 2008), spray-freeze drying (Niwa & Danjo, 2013), freeze
drying (Kim & Lee, 2010; Tuomela et al., 2015) and vacuum drying (Choi et al., 2008;
Kim & Lee, 2010) to name a few widely used drying techniques. Each has their own
pros/cons. For example, the ability to rapidly dry, prevent microbial growth, eliminate
degradation of heat-sensitive compounds, and have rapid reconstitution times for
parenteral drugs are all characteristic of freeze drying (Khairnar et al., 2012). However, the
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method of freeze drying is extremely costly and it is not conducted as a continuous process
(Khairnar et al., 2012). With fluidized bed coating, an effective drying with high thermal
efficiency and control over temperature makes it ideal for sensitive compounds, but
produces composites with low drug loading due to the use of a substrate and does not
process unique particles with needle like morphology (Chua & Chou, 2005). Moreover,
preparing nanocomposites with high drug loading (>50%) is very time consuming and
costly.
Spray drying has many benefits toward drying of suspensions into composites, that
includes the cost effective nature of spray drying, the ability to scale from the lab to
industrial manufacturing with ease and the wide array of applications that has already been
applied using a spray drying as the method of drying composites (A. Bhakay et al., 2014;
Bilgili et al., 2018; Chaubal & Popescu, 2008; Jain et al., 2012; Poozesh & Bilgili, 2019;
Rahman et al., 2019). The disadvantages of a spray drying approach to drying suspensions
results from the relatively low bulk density (due to high Peclet number during evaporation)
and poor flowability of the spray-dried powder. Moreover, the particles having an inflated
shell morphology can pose a risk to tablet cracking from differential density zones leading
to elastic recoil and stress relief (Eiliazadeh et al., 2003; Vehring, 2008).
Thin Film Evaporator (TFE) has recently made its appearance into the
pharmaceutical industry to aid in the continuous production of composites (Lee et al.,
2020). A TFE is traditionally found within the food industry and is used to concentrate a
liquid or suspension stream for use in products such as the dairy industry for skim milk or
orange concentrates where a short contact time with a heated surface does not degrade the
product being concentrated (Tanguy et al., 2015; Tateo, 1990). The TFE contains a rotating
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assemble within a heated barrel that is under a vacuum to aid in driving off the solvent
from the process stream, thus concentrating and drying the incoming solution or suspension
(Lee et al., 2020). The “thin film” refers to the thickness of the traveling stream through
the unit between the barrel and rotating assemble which is scraped and moved along the
barrel to maintain a constant film of about 0.5 mm that will make for higher surface area
and easy evaporation of solvent from the stream (Lee et al., 2020). These characteristics of
a TFE are great conditions for the concentration of solutions and suspensions, but if taken
one step forward under higher temperatures and shorter residence time through the barrel,
one can use the TFE to generate dried composites like those produced by a spray dryer.
Due to this, the use and application of TFE can be very beneficial in generating composites
as an alternative to spray drying as a continuous processing unit.
To study this technology within the lab, a bench scale analogous unit to generate a
thin film under vacuum and varying temperature was sought after as an alternative running
the TFE at manufacturing scale. The rotary evaporator which consists of a spinning round
bottom flask placed in a temperature-controlled bath under vacuum was chosen to simulate
the drying kinetics in a TFE. The use of a rotary evaporator creates a thin film within a
round bottom flask that is like that of a TFE. In literature, the use of a rotary evaporator
has been used on distillation or drying of non-pharmaceutical drugs (Zhong et al., 2016).
The implementation of a rotary evaporator has only recently made its way to being used
for the drying of pharmaceuticals (Gade et al., 2020; Saboo et al., 2020).
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1.2.3 Redispersion and Drug Release from Nanocomposites
Testing of drug nanocomposites must be conducted to establish the impact of
formulation–process variables in vitro before further studies are conducted in vivo. To
do so, redispersion and dissolution are traditional methods for testing the effects of
formulations before in vivo studies are conducted (A. Bhakay et al., 2014; Anagha
Bhakay et al., 2014; Bhakay, Rahman, et al., 2018; Ghazal et al., 2009; Jackson et al.,
2016; Li, 2017; Norbert Rasenack, 2002; Van Eerdenbrugh et al., 2008). Bhakay et al.
(2018b) demonstrated that redispersion testing could be useful for the characterization of
nanocomposites ability to disperse nanoparticles into an aqueous media (A. Bhakay et
al., 2014; Bhakay, Rahman, et al., 2018). Multiple groups conducted studies involving
dissolution testing as the method of characterizing the differences in formulations and
their performance on enhancing the therapeutic delivery (Azad et al., 2016; Anagha
Bhakay et al., 2014; Bilgili et al., 2018; Jackson et al., 2016; Norbert Rasenack, 2002;
Van Eerdenbrugh et al., 2008). Although dissolution testing is a staple of understanding
the performance of a formulation, it does not predict the in vivo performance. Hence, the
use of redispersion testing could complement our understanding of nanocomposites;
which may be more discerning than traditional dissolution tests and more representative
of the in vivo conditions (A. Bhakay et al., 2014; Bhakay et al., 2013).
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1.3 Objectives
The specific objectives of this research are to:
1. Develop an understanding of the impacts of the polymers on the particle size and
stability of wet-milled drug suspensions and prepare a suitable precursor drug
nanosuspension for use in the rotary evaporation studies.
2. Examine the effects of varying drying conditions on the preparation of rotary
evaporated nanocomposites.
3. Investigate different processing methods to generate repeatable and consistent
nanocomposites.
4. Discern the impact of different polymers/surfactants on the reconstitution of
nanoparticles from nanocomposites (redispersion).
5. Analyze the effect of polymers/surfactants on drug release from the rotary evaporated
nanocomposites vs. spray-dried nanocomposites

1.4 Thesis Outline
This thesis has been structured into the following chapters. Chapter 2 examines the milling
of itraconazole, and the impact different polymers have on the stability of suspension. The
use of different polymers to improve on formulation stability and assist with aggregation
was demonstrated in this chapter. In Chapter 3, the drying of nanosuspensions using a
rotary evaporator will continue to evaluate formulations and use of polymers to prevent
aggregation in the transition from a suspension to a powder. The processing conditions and
the addition of post processing homogenization was explored in Chapter 3. For Chapter 4,
an emphasis on the redispersion was conducted to study the recovery of nanoparticles from
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generated nanocomposites produced by the rotary evaporator and supporting dissolution
data was generated to show the relationship of redispersion to that of dissolution. Finally,
Chapter 5 will provide the summary from this body of work as well as the
recommendations and thoughts for future work that will build off this thesis.
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CHAPTER 2
NANOSUSPENSIONS PREPARATION AND CHARACTERIZATION

We investigate the impact of different polymers on the preparation of wet-milled
suspensions of itraconazole (ITZ). Suspensions were milled using a Netzsch Minicer wet
media mill to prepare ITZ nanosuspensions. Different classes of polymers were added to
an existing stable drug nanosuspension to assist in downstream processing. The use of
hydroxypropyl cellulose SL grade, polyvinylpyrrolidone K30, polyethylene glycol 3350,
Kollidon VA64, and Pluronic F-127 were all explored as water-soluble polymers to aid in
processing of nanosuspensions. These polymers all contributed to different characteristics
of the suspension and changed the properties of downstream nanocomposites that will be
discussed in the subsequent chapters. In this chapter, a focus on the preparation of stable
ITZ nanosuspension and formulation will be done.

2.1 Materials and Methods
2.1.1 Materials
Itraconazole (ITZ) was purchased from Green Chempharm Inc. (Bardonia, NY, USA).
Solubility of ITZ in deionized water is 0.002 µg/ml (Ghazal et al., 2009), which makes it a
model Biopharmaceutical Classification System (BCS) Class II drug. Hydroxypropyl
cellulose SL grade (HPC SL) with a molecular weight of 100 kg/mol was obtained from
Nisso America Inc. (New York, NY, USA). Sodium dodecyl sulfate (SDS) was purchased
from Sigma-Aldrich (Milwaukee, WI, USA). Polyvinylpyrrolidone K30 (PVP K30) with
a molecular weight of 50 kg/mol was purchased from AppliChem GmbHP (Darmstadt,
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Germany). Polyethylene Glycol 3350 (PEG 3350) with a molecular weight of 3350 g/mol
was obtained from Spectrum Chemical MFG Corp. (Gardena, CA, USA). Kollidon VA64
(VA64) with an average molecular weight of 57,500 g/mol was purchased from BASF
(Lampertheim, Germany). Pluronic F-127 (F-127) was purchased from Sigma-Aldrich
(Milwaukee, WI, USA). Yttrium-stabilized zirconia, which is highly wear resistant, with a
nominal size of 400 µm was purchased from Norstone Inc. (Bridgeport, PA, USA).
2.1.2 Formulations and Wet Stirred Media Milling
All formulations used in the study for the preparation of suspensions are presented in Table
2.1. The percentages of dispersants within each formulation are on a w/w basis with respect
to the total weight of deionized water (300 g). In each formulation, an ITZ percentage was
kept at 10%. The basis for all formulations stems from a known effective suspension
composition of 10% ITZ–2.5% HPC-SL–0.2% SDS, which has been shown to produce
nanocomposites and stabilize ITZ after milling (Bilgili et al., 2018).

15

Table 2.1 Formulations of the Milled Suspensions

a
b

a

Polymer type/grade

MW (g/mol)

HPC SL
HPC SL
HPC SL
HPC SL
HPC SL/PVP K30 (1:1)
HPC SL/PVP K30 (1:2)
HPC SL/PVP K30 (1:3)
HPC SL/PEG 3350 (1:1)
HPC SL/PEG 3350 (1:2)
HPC SL/PEG 3350 (1:3)
HPC SL/ VA64(1:1)
HPC SL/VA64 (1:2)
HPC SL/VA64 (1:3)
HPC SL/F-127 (3.6:1)
HPC SL/F-127 (1:1)
HPC SL/F-127 (1:2)

100,000
100,000
100,000
100,000
100,000/ 65,000
100,000/ 65,000
100,000/ 65,000
100,000/ 3,350
100,000/ 3,350
100,000/ 3,350
100,000/ 57,500
100,000/ 57,500
100,000/ 57,500
100,000/ 12,600
100,000/ 12,600
100,000/ 12,600

Suspension content
Polymer
SDS
(% w/w)b
(% w/w)b
2.5
0.2
5
0.2
7.5
0.2
10
0.2
5
0.2
7.5
0.2
10
0.2
5
0.2
7.5
0.2
10
0.2
5
0.2
7.5
0.2
10
0.2
3.2
0.2
5
0.2
7.5
0.2

MW is Molecular Weight of the polymers.
All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (300 g).

An overhead mixer (Chemglass, CG-2051-020, Vineland, NJ) was setup over an
800 ml beaker to disperse the ITZ particles and other excipients. The suspension was then
transferred over to a holding tank on the Netzsch wet stirred media mill (Minicer, Netzsch,
Selb, Germany) (Figure 2.1). Milling conditions were adapted from previous milling study
using the Netzsch Microcer conditions of 196 g bead loading and 126 ml/min recirculation
rate (Bilgili et al., 2018). Milling conditions explored included the 160 ml chamber filled
between 343–525 g of 0.4 mm zirconia beads and a screen orientation of 0.15 mm. The
suspension was recirculated through the milling chamber at a rate between 189–252
mL/min with a Masterflex L/S peristaltic pump (Radnor, PA, USA) and C-Flex L/S 17
tubing while milled at a rotor speed of 4000 rpm over a time of 65 min. The milling
chamber and holding tank were both cooled by a chiller (Huber Unistat 405w, Huber,
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Offenburg, Germany) to maintain the temperature of the suspension below 33 ºC. Particle
size was taken at various time points to track the progression of milling over time.
Suspensions were saved in a fridge at 4.4 ºC before drying.

Figure 2.1 Schematic of Netzsch Media mill in the recirculation mode (left) and
photograph of the setup in the laboratory (right).
2.1.3 Particle Size Analysis
Particle size distribution (PSD) of all samples was performed by Mastersizer 3000 laser
diffraction particle size analyzer with Hydro MV cell (Malvern Panalytical, United
Kingdom) using red and blue light and a detection range of 0.01 µm to 3500 µm (Figure
2.2). Dispersant cell was set at a stir rate of 1500 rpm and sonicated for 30 s at 60%
intensity. Mie scattering theory was used to compute the volume-based distribution with a
refractive index of 1.68 for ITZ and 1.33 for deionized water (Bilgili et al., 2018). An
alignment of the system followed by a background measurement of 10 s for red and 10 s
for blue light was taken before each set of readings. Three measurements averaged were
taken and reported. Method used was set around repeatable results from measurement to
measurement on various samples following ISO model within the Malvern Software.
During measurement, the sample was added until obscuration fell between the ranges of 3
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to 8%. Suspensions were measured during milling as well as prior to drying to ensure that
all suspensions retained their PSD.

Figure 2.2 Mastersizer 3000 with Hydro MV Dispersion Unit.
2.1.4 Nanosuspensions with Additional Dispersants
The baseline nanosuspension consisted of 10% ITZ, 2.5% HPC-SL, and 0.2% SDS. A third
(soluble) dispersant or additional HPC-SL was added to the existing stable nanosuspension
to generate more nanosuspensions to test for drying and modulate the redispersibility/drug
release from the nanocomposites. The help of a stir bar within a secondary vial was used
to mix the nanosuspension with the additional dispersant to completely dissolve it in the
nanosuspension. For each formulation above baseline, mentioned in Table 2.1, this was
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performed, and the PSD of the following intermediate suspension was also measured by
laser diffraction to confirm particle size from the nanosuspension was preserved prior to
drying ensuring no aggregation occurred during production and storage. In general, all
samples were prepared and dried within 7 days of preparing the suspension to reduce the
risk of aggregation over time as previous studies have demonstrated (Bilgili et al., 2018;
Rahman et al., 2019).

2.2 Results and Discussion
2.2.1 Particle Breakage During Wet Media Milling
As-received ITZ particles had a median size D50 of 15.5 µm and 90% passing size of D90
45.8 µm, as measured via Rodos/Helos laser diffraction system (Bilgili et al., 2018). The
suspension with the baseline formulation (10%ITZ, 2.5%HPC-SL, and 0.2%SDS) was
milled for a total time of 65 min with the goal to produce a nanosuspension all particles
below 1 µm, preferably with a median size below 200 nm, to ensure that significant
dissolution enhancement can be achieved from the nanocomposites. Figure 2.3 illustrates
the time-wise evolution of characteristic particle sizes, i.e., the median drug particle size
D50, 90% passing particle size D90, and the cumulative volume percentage of
colloidal/nanoparticles Q (1 µm) for multiple milling runs of which were performed with
the same formulation under different conditions. All runs exhibited monotonic decrease in
D50 and D90 and increase in Q (1 µm), which suggests particle breakage is the dominant
mechanism, and severe aggregation of the milled particles did not occur, showing the
feasibility of the baseline formulation. The sizes tended to approach a D50 of ~0.130 µm
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and a D90 of ~0.330 µm. This corresponds to a remarkable size reduction ratio of ~120
based on D50, which is hard to achieve in any other size reduction equipment.
Although most milling conditions did not show drastic changes in the final milled
particle sizes, the total experimental effort/time was affected due to excessive heat
generation from the higher bead loading condition and associated multiple shutdowns of
the mill to maintain the suspension temperature below 33 ºC set limit. Ultimately, running
at a 2x bead loading of 392 g and a 1.5x pump rate of 189 ml/min for the suspension volume
of 300 ml were the best conditions for milling with the Minicer chamber. A very similar
PSD to that of higher bead loading was achieved as well as a complete nanoparticle
suspension which required few shutdowns of the mill and contributed to a great milling
experience.
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Figure 2.3 Progression of characteristic particle sizes of the nanosuspensions as a function
of time under different milling conditions of bead loading and pump rate. All suspensions
milled used a stable formulation of 10%ITZ, 2.5%HPC-SL, and 0.2%SDS.
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2.2.2 Nanosuspension Stability and Dispersant Analysis
Let us now transition to examination of the impact of additional dispersant. After the
preparation of the baseline nanosuspension (10%ITZ, 2.5%HPC-SL, and 0.2%SDS),
which is prepared fresh for each final formulation, a third dispersant or additional HPC-SL
was dissolved in the nanosuspension to prepare the final makeup of the formulation. Since
each additional dispersant was water soluble, little to no change in the particle size of the
starting suspension was to be expected. To confirm this hypothesis, the particle sizes of
each final suspension was measured again to compare with the particle sizes of the baseline
nanosuspension. These values can be seen in Table 2.2 for the particle size of each
suspension after milling followed by the measurement after the addition of each dispersant.
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Table 2.2 Nanosuspension PSD After Milling and Formulating: Stability Post Processing
Particle size post milling
Suspension
Formulationa

D50±S
D
(µm)

D90±S
D
(µm)

Q
(1µm)
±SD
(%)

2.5%HPC-SL

0.132±
0.00

0.316±
0.00

5%HPC-SL

0.132±
0.00

7.5%HPC-SL

Particle size post
formulating/stability
verificationb
D50± SD
(µm)

D90±S
D
(µm)

Q
(1µm)
±SD
(%)

100±
0.00

0.135±
0.00

0.345±
0.00

99.93±
0.00

0.316±
0.00

100±
0.00

0.143±
0.00

0.379±
0.01

98.65±
0.02

0.132±
0.00

0.316±
0.00

100±
0.00

0.148±
0.00

0.405±
0.01

99.06±
0.03

10%HPC-SL

0.132±
0.00

0.316±
0.00

100±
0.00

0.152±
0.00

0.414±
0.02

99.63±
0.53

2.5%HPC-SL/
2.5%PVP K30

0.129±
0.00

0.308±
0.00

100±
0.00

0.133±
0.01

0.328±
0.02

100±
0.00

2.5%HPC-SL/
5%PVP K30

0.132±
0.00

0.316±
0.00

100±
0.00

0.139±
0.00

0.346±
0.00

100±
0.00

2.5%HPC-SL/
7.5%PVP K30

0.132±
0.00

0.316±
0.00

100±
0.00

0.145±
0.01

0.383±
0.03

99.16±
0.49

2.5%HPC-SL/
2.5%PEG 3350

0.129±
0.00

0.308±
0.00

100±
0.00

0.130±
0.00

0.322±
0.01

100±
0.00

2.5%HPC-SL/
5%PEG 3350

0.132±
0.00

0.316±
0.00

100±
0.00

0.133±
0.00

0.336±
0.00

100±
0.00

2.5%HPC-SL/
7.5%PEG 3350

0.132±
0.00

0.316±
0.00

100±
0.00

0.146±
0.01

0.379±
0.03

99.29±
0.62

2.5%HPC-SL/
2.5%VA 64

0.129±
0.00

0.308±
0.00

100±
0.00

0.138±
0.01

0.385±
0.08

98.01±
2.19

2.5%HPC-SL/
5%VA 64

0.132±
0.00

0.316±
0.00

100±
0.00

0.134±
0.00

0.334±
0.00

100±
0.00

2.5%HPC-SL/
7.5%VA 64

0.132±
0.00

0.316±
0.00

100±
0.00

0.137±
0.00

0.351±
0.00

99.98±
0.03
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2.5%HPC-SL/
0.7%F-127

0.132±
0.00

0.316±
0.00

100±
0.00

0.137±
0.00

0.342±
0.01

100±
0.00

2.5%HPC-SL/
2.5%F-127

0.129±
0.00

0.308±
0.00

100±
0.00

0.132±
0.01

0.325±
0.02

100±
0.00

2.5%HPC-SL/
5%F-127

0.132±
0.00

0.316±
0.00

100±
0.00

0.136±
0.00c

0.337±
0.00c

100±
0.00c

a

All suspensions have 10% ITZ and 0.2% SDS. %w/w is with respect to the weight of deionized water (300
g).
b
Intermediate suspensions with additional dispersants were prepared and dried within 7 days of suspension
nanomilling.
c
Particle size measured 12 days after preparation for long term stability.

The first three columns of Table 2.2 show almost identical particle sizes, within a
few percent, because they correspond to the freshly prepared nanosuspensions with the
baseline formulation, which demonstrates the reproducibility of the wet stirred media
milling process. The last three columns correspond to particle sizes of the baseline
suspensions after the supplement of a new dispersant or additional HPC-SL. Except for
HPC-SL at higher concentrations, the addition of different dispersants led to <10% increase
in D50 and up to 25% increase in D90. HPC-SL add to highest increase: up to 15% in D50
and up to 31% increase in D90. While these increases are statistically significant (due to
0.0% SD of most laser diffraction measurements), the nanosuspensions remained colloidal;
all final nanosuspensions had D50 below 150 nm and D90 below 400 nm, except the 10%
HPC-SL nanosuspension.
With formulations containing F-127, a triblock copolymer (a polymeric surfactant),
the stability was tested up to 12 days after preparation with 5% concentration. This was
done to show stability and investigate Ostwald ripening which can occur at concentrations
above the critical micellization concentration (CMC) as is the case with formulations
containing more than 0.7% F-127 (Alexandridis et al., 1994; Knieke et al., 2013). Looking
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at the particle size of the formulated suspension in Table 2.2, one can see there was no
significant growth to the nanoparticles during the extended hold time that would be cause
for concern with Ostwald ripening. Overall, each formulation was successful in generating
and maintaining a nanosuspension that can and will be used for further downstream
processing.

2.3 Conclusions
This study has demonstrated a successful scale-up of wet media milling of ITZ suspensions
from the Netzsch Microcer mill to the Netzsch Minicer mill. All the milling conditions
tested, from low to high bead loading as well as low to high pump rate showed there was
an achievable sweet spot which allowed for similar particle size reduction as compared to
that of high bead loading conditions. This allows for reasonable milling times to produce
the nanosuspensions without costly time spent on milling. The conditions utilizing a
chamber fill of 392 g of beads and a recirculation rate of 189 ml/min returned the best
balance of heat generation and total milling time to generate the nanosuspension. The
baseline formulation (10% ITZ, 2.5% HPC-SL, and 0.2% SDS) enabled suppression of
severe aggregation. Addition of other dispersants or extra HPC did not cause a drastic size
increase during the storage (before drying). In most of the formulations, ITZ suspensions
with D50 below 150 nm and D90 below 400 nm were formed. The addition of the polymeric
surfactant (Pluronic F-127) above CMC did not impact particle size growth in short term.
Overall, all these nanosuspensions can be used in the drying process as precursor to
nanocomposites.
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CHAPTER 3
NANOCOMPOSITES AND IMPACT OF PROCESSING: A DIFFERENT WAY
OF PRODUCING NANOCOMPOSITES

In Chapter 2, itraconazole (ITZ) nanosuspensions with various polymers/surfactants were
prepared successfully by a wet stirred media milling process. Here, we prepared drug
nanocomposites, using the drug nanosuspensions as precursor, via a new evaporative
isolation method of rotary evaporation. These nanocomposites were collected from the
round bottom flask in the system and processing via mortar and pestle was performed to
homogenize the dried nanocomposites. In addition, different ways of introducing the
nanosuspension to the flask were explored to study the impact of a distillation approach
compared to that of a feed and bleed with shots of suspension being fed into the round
bottom flask while under full vacuum. The combination of different processing methods
led to significant insights into the drying of drug nanosuspensions using the rotary
evaporator.

3.1 Materials and Methods
3.1.1 Materials
Itraconazole (ITZ) was purchased from Green Chempharm Inc. (Bardonia, NY, USA).
Hydroxypropyl cellulose SL grade (HPC SL) with a molecular weight of 100 kg/mol was
obtained from Nisso America Inc. (New York, NY, USA). Sodium dodecyl sulfate (SDS)
was purchased from Sigma-Aldrich (Milwaukee, WI, USA). Polyvinylpyrrolidone K30
(PVP K30) with a molecular weight of 50 kg/mol was purchased from AppliChem GmbH
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(Darmstadt, Germany). Polyethylene Glycol 3350 (PEG 3350) with a molecular weight of
3350 g/mol was obtained from Spectrum Chemical MFG Corp. (Gardena, CA, USA).
Kollidon VA64 (VA64) with an average molecular weight of 57,500 g/mol was purchased
from BASF (Lampertheim, Germany). Pluronic F-127 (F-127) was purchased from SigmaAldrich (Milwaukee, WI, USA).
3.1.2 Formation of Nanocomposites via Rotary Evaporation
The milled prepared ITZ suspensions with added dispersants (refer to Chapter 2) were dried
within 7 days of preparation and storage using a Rotavapor R-300 (Buchi, New Castle, DE,
USA). The unit was either run in batch distillation mode where suspensions were placed
within a round bottom flask and “distilled” dry by having the bath temperature set at 60 ºC
and a vacuum below 300 mmHg absolute was pulled until suspension appeared to be dry,
evident of no condensation forming on the cold finger of the Rotavapor followed by a
10min hold under 3 mmHg to continue drying the nanocomposite. Alternatively, the
Rotavapor was operated in feed and bleed mode where suspension was fed into the round
bottom via a tube with a valve while under a vacuum of 3 mmHg absolute and a bath
temperature of 90 ºC (Figure 3.1). Bursts of suspension were fed until the entire prepared
suspension was processed and condensation stopped followed by additional drying for 10
mins to ensure complete evaporation of water.
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Figure 3.1 Rotavapor setup for drying nanosuspensions using feed and bleed method.
3.1.3 Processing Rotary Evaporated Nanocomposites
Rotary evaporated nanocomposites adhered to the round bottom flasks were scrapped off
using a combination of a Chem-spin scraper tool on a handheld drill (Chemglass, Vineland,
NJ, USA) and a spatula (Figure 3.2right). The Chem-spin scraper was first used to collect
the bulk of solids from within the round bottom flask followed by manual scraping with a
spatula for collecting the last bit of solids. The collected nanocomposite samples were then
transferred over to a mortar (Figure 3.2right). to be ground with medium to light pressure
for 5 min, thus improving the homogeneity of each sample.
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Figure 3.2 Nanocomposite after scraping with Chem-spin and spatula (left). Mortar and
Pestle (MP) (top right), Chem-spin (left of MP), and spatula used to scrape round bottom
flasks (bottom right) (right).
3.1.4 Particle Sizing
Particle size of nanocomposites was measured by HELOS/KR laser diffraction
sensor in combination with the RODOS dispersion unit (Sympatec, Pennington, NJ, USA)
running Fraunhofer theory. Three measurements were averaged to obtain a stable reading.
Each sample went onto the vibratory chute set at 65% intensity and a dispersion pressure
of 1.0 bar was used. To capture the wide variety of PSDs the R6 lens was used for all
measurements which had a measurement range of 9–1750 µm (Figure 3.3).
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Figure 3.3 HELOS/KR Laser with RODOS Dispersion Unit.
3.2 Results and Discussion
3.2.1 Properties of the Nanocomposites
The previously prepared nanosuspensions from Chapter 2 (Table 2.2) were dried by the
Rotavapor to form the nanocomposites. Upon initial investigation of utilizing the
equipment, the use of a bath temperature of 60 ºC and a distillation approach was first
tested using the baseline formulation of 10%ITZ, 2.5% HPC-SL, and 0.2% SDS. This
initial test returned a nanocomposite that was very coarse when scraped off the round
bottom flask and posed numerous challenges with generating reproduceable particle size
readings as well as gathering further downstream data in other analyses. In Table 3.1, we
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can see the clear particle size variation in the samples obtained from scraping the
nanocomposites off the round bottom flask.

Table 3.1 Particle Sizes of the Nanocomposites from Rotavapor without Further
Downstream Processing
Nanocomposite Particle Size
Volume
Measurement

Formulationa

Mean
D10 (µm)

D50 (µm)

D90 (µm)
Distribution
(VMD) (µm)

a

1

2.5HPC-SL

82.0

240.0

739.0

336.1

2

2.5HPC-SL

97.0

290.2

731.7

356.2

3

2.5HPC-SL

150.5

457.6

1372

614.2

4

2.5HPC-SL

161.4

612.9

1476

747.1

Average

122.7

400.2

1080

513.4

Standard Deviation

33.9

146.9

346.3

173.9

Baseline precursor nanosuspension contained 10% ITZ 2.5% HPC-SL and 0.2% SDS.

The variations illustrated in Table 3.1 must be eliminated or minimized to generate
reproduceable and reliable results. As a result, we augmented the use of the Chem-spin as
well as a few minutes of mortar and pestle to the post processing of each rotary evaporated
sample. Since mortar and pestle was a very strenuous task on one individual, two time
points of 5 min and 10 min was explored. The first time point at 5 min of mortar and pestle,
returned a much more homogenous nanocomposite which reflected in the SD of the
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measurements performed (Table 3.2). With the additional use of mortar and pestle up to 10
min, a slight improvement was seen over the 5min reading with the X90 SD (Table 3.2).
With this data in mind the decision to use 5min of mortar and pestle was carried out for all
experiments since 10 min of mortar and pestle was a physically demanding task to be
executed for little to no improvement in the overall sample homogeneity.

Table 3.2 Particle Sizes of Nanocomposites after Mortar and Pestle Milling
Nanocomposite Particle Size
Volume
Measurementa

Mean
D10 (µm)

D50 (µm)

D90 (µm)
Distribution
(VMD) (µm)

Average
5 min

11.5

91.3

238.0

108.5

0.5

4.7

16.3

5.4

Average

9.6

72.6

198.0

90.0

Standard

0.4

6.0

8.4

5.3

Standard
Deviation

10 min

Deviation
a

Baseline precursor nanosuspension contained 10% ITZ 2.5% HPC-SL and 0.2% SDS.

3.2.2 Other Drying Challenges
Let us now examine other challenges that were observed with the use of HPC within the
formulations. Even after a homogenous nanocomposite generated upon using a mortar and
pestle step, there were still issues with downstream testing and release of nanoparticles
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from the nanocomposites. HPC has a very low cloud point of ~40 ºC despite its very good
solubility at room temperature (Khuman et al., 2014). Hence, the concern for HPC
precipitating during the drying of the nanosuspensions was raised when nanoparticle
recover was next to nothing. As was shown in a previous study, HPC is crucial to the
stability of the nanosuspension (Bilgili et al., 2018). Without it, a nanosuspension cannot
be formed or stabilized against the aggregation of ITZ nanoparticles. With the precipitation
of HPC at the processing conditions of the Rotavapor, the nanosuspension is allowed to
aggregate and show little to no nanoparticle recovery. To this end, a modified approach to
drying nanosuspensions was adopted with the prevention of nanoparticle aggregation due
to potential HPC precipitation. The goal was to switch from a distillation to one that would
not allow the suspension to be dried without heating past the cloud point of HPC. For that
to occur, the feed and bleed method was adopted where a tube was passed into the round
bottom flask and small bursts of suspension were fed into the flask that was both heated at
90 ºC and under 3 mmHg absolute vacuum. This process allows for instantaneous
evaporation of the water from the suspension and drying to generate a nanocomposite that
would not see a high temperature with the assistance of evaporative cooling. All proceeding
suspensions were processed utilizing this technique for the prevention of HPC precipitation
followed by the previously mentioned use of a mortar and pestle step to ensure the
uniformity of the nanocomposites. All nanosuspension PSDs followed by their respective
nanocomposite particle size can be seen in Table 3.3. Due to different types/molecular
weight/loadings of the polymers and surfactants and perhaps their complex interactions,
the nanocomposite particle sizes varied considerably. The median size D50 ranged from 62
µm to 288 µm, whereas D90 ranged from 214 µm to 680 µm. However, the standard
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deviation (SD) values in Table 3.3. and the relative standard deviation values (RSD, not
shown) were much smaller than that presented in Table 3.1 for the nanocomposite without
process optimization. Establishing strong correlations between the nanocomposite particle
sizes and polymer properties will likely be difficult. However, in general, addition of a
third dispersant (besides HPC-SL and SDS) or additional HPC semes to have resulted in
coarser nanocomposite particles although there are trend-breaking formulations.
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Table 3.3 Particle Sizes of the Nanosuspensions and the Nanocomposites Prepared via
Drying (with Feed and Bleed)/Mortar and Pestle Milling
Particle size post milling

Nanocomposite Particle size

D50±S
D (µm)

D90±S
D (µm)

Q
(1µm)
±SD
(%)

D50± SD
(µm)

D90±SD
(µm)

VMD
±SD
(µm)

2.5%HPC-SL

0.132±
0.00

0.316±
0.00

100±
0.00

66.5±
4.7

186.9±
18.6

85.6±8
.0

5%HPC-SL

0.132±
0.00

0.316±
0.00

100±
0.00

222.4±
22.8

608.0±
73.2

279.0±
30.9

7.5%HPC-SL

0.132±
0.00

0.316±
0.00

100±
0.00

122.0±
4.1

329.0±
8.2

151.9±
4.1

10%HPC-SL

0.132±
0.00

0.316±
0.00

100±
0.00

287.7±
57.2

679.8±
49.0

335.2±
43.9

2.5%HPC-SL/
2.5%PVP K30

0.129±
0.00

0.308±
0.00

100±
0.00

122.3±
6.5

355.9±
9.4

157.8±
5.5

2.5%HPC-SL/
5%PVP K30

0.132±
0.00

0.316±
0.00

100±
0.00

109.6±
12.9

354.3±
30.2

146.5±
10.6

2.5%HPC-SL/
7.5%PVP K30

0.132±
0.00

0.316±
0.00

100±
0.00

108.7±
2.9

395.0±
9.9

161.3±
1.3

2.5%HPC-SL/
2.5%PEG
3350

0.129±
0.00

0.308±
0.00

100±
0.00

127.4±
5.7

349.5±
3.7

160.1±
4.1

2.5%HPC-SL/
5%PEG 3350

0.132±
0.00

0.316±
0.00

100±
0.00

157.1±
10.6

386.8±
30.2

185.4±
13.6

2.5%HPC-SL/
7.5%PEG
3350

0.132±
0.00

0.316±
0.00

100±
0.00

133.1±
10.5

417.2±
30.6

181.7±
13.6

2.5%HPC-SL/
2.5%VA 64

0.129±
0.00

0.308±
0.00

100±
0.00

100.4±
14.1

302.2±
20.6

133.1±
12.0

2.5%HPC-SL/
5%VA 64

0.132±
0.00

0.316±
0.00

100±
0.00

134±6.
6

339±24
.9

167±5.
5

Suspension
Formulationa
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2.5%HPC-SL/
7.5%VA 64

0.132±
0.00

0.316±
0.00

100±
0.00

87.5±3
.0

304.9±
7.9

126.5±
3.1

2.5%HPC-SL/
0.7%F-127

0.132±
0.00

0.316±
0.00

100±
0.00

62.0±8
.9

213.9±
28.7

92.0±1
2.7

2.5%HPC-SL/
2.5%F-127

0.129±
0.00

0.308±
0.00

100±
0.00

136.4±
9.0

375.7±
5.7

172.9±
4.5

2.5%HPC-SL/
5%F-127

0.132±
0.00

0.316±
0.00

100±
0.00

108.1±
10.4

341.4±
21.7

149.8±
11.4

a

All suspensions have 10% ITZ and 0.2% SDS. %w/w is with respect to the weight of deionized water (300
g).

3.3 Conclusions
A robust rotary evaporation (drying) process was developed with feed and bleed type
introduction of drug nanosuspensions, followed by mortar and pestle milling of the
produced nanocomposites. This approach enabled one to prepare a more relatively
homogeneous/uniform nanocomposite powder than that without the optimization of the
processing steps. In the redispersion and dissolution tests, some confounding impact of the
nanocomposite particle size is to be expected.
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CHAPTER 4
IMPACT OF DISPERSANTS ON DRUG REDISPERSION AND DISSOLUTION

In this chapter, the impact of formulation and drying conditions on the redispersion and
dissolution of the drug nanocomposites prepared by the optimized rotary evaporation
process is examined. A detailed analysis of the results will elucidate the roles of various
types/loadings of the dispersants on the redispersibility and drug release. Based on in vitro
drug release profiles, the impact of drug particle size and nanocomposite particle size will
be scrutinized. Finally, formulations that lead to fast, immediate drug release (80% release
in 20 min) during the in vitro dissolution will be identified as lead formulations for
bioavailability enhancement. It is critical to mention that all labels for the nanocomposites
are based on the composition of the respective precursor drug nanosuspensions. All drug
nanosuspensions contain a baseline formulation of 10% ITZ, 2.5% HPC-SL, and 0.2% SDS
on a wet basis. Obviously, the “dry” nanocomposites do not contain 10% ITZ, for example.
Other precursor nanosuspensions were prepared by adding a third dispersant or extra HPCSL to the baseline nanosuspension. Since all these nanosuspensions contain 10% ITZ and
0.2% SDS, their labeling will only mention HPC-SL concentration and the third dispersant
concentration (PVP K30, PEG 3350, Kollidon VA64, and Pluronic F-127).
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4.1 Materials and Methods
4.1.1 Materials
Itraconazole (ITZ) was purchased from Green Chempharm Inc. (Bardonia, NY, USA).
Hydroxypropyl cellulose SL grade (HPC SL) with a molecular weight of 100 kg/mol was
obtained from Nisso America Inc. (New York, NY, USA). Sodium dodecyl sulfate (SDS)
was purchased from Sigma-Aldrich (Milwaukee, WI, USA). Polyvinylpyrrolidone K30
(PVP K30) with a molecular weight of 50 kg/mol was purchased from AppliChem GmbH
(Darmstadt, Germany). Polyethylene Glycol 3350 (PEG 3350) with a molecular weight of
3350 g/mol was obtained from Spectrum Chemical MFG Corp. (Gardena, CA, USA).
Kollidon VA64 (VA64) with an average molecular weight of 57,500 g/mol was purchased
from BASF (Lampertheim, Germany). Pluronic F-127 (F-127) was purchased from SigmaAldrich (Milwaukee, WI, USA).
4.1.2 Redispersion of Nanocomposites
The redispersion of nanocomposites produced by rotary evaporation was performed using
the method in (Bilgili et al., 2018). A 50 ml beaker with 30 ml of 3.0 g/L SDS solution was
placed under an overhead mixer (Chemglass, CG-2051-020, Vineland, NJ) set at a speed
of 400 rpm with a 4 blade 25 mm downward pitched impeller on a Mettler Toledo stir shaft
(Figure 4.1). Nanocomposite samples containing 0.394 g ITZ basis were mixed with the
SDS solution in the beaker at room temperature (see table 4.1 for drug content in each
formulation). A 0.5 ml aliquot from the mixed suspension was taken at three different time
points of 2 min, 10 min, and 30 min and measured directly by laser diffraction. Two runs
were performed for each sample to obtain an average and show reproducibility in the
results. With this drug to solution ratio, the dispersants could completely dissolve and
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release the ITZ with little ITZ dissolution and no concern with generating a solution
concentration close to the CMC of F-127 (Alexandridis et al., 1994; Bilgili et al., 2018).

Figure 4.1 Redispersion apparatus with overhead stirrer.
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Table 4.1 Theoretical Drug Loading of Nanocomposites
Polymer type/grade
HPC SL
HPC SL
HPC SL
HPC SL
HPC SL/PVP K30
(1:1)
HPC SL/PVP K30
(1:2)
HPC SL/PVP K30
(1:3)
HPC SL/PEG 3350
(1:1)
HPC SL/PEG 3350
(1:2)
HPC SL/PEG 3350
(1:3)
HPC SL/ VA64(1:1)
HPC SL/VA64 (1:2)
HPC SL/VA64 (1:3)
HPC SL/F-127 (3.6:1)
HPC SL/F-127 (1:1)
HPC SL/F-127 (1:2)
a

Nanocomposite Formulation
Polymer
SDS
(% w/w)a
(% w/w)a
2.5
0.2
5
0.2
7.5
0.2
10
0.2

Theoretical Drug Content (%)
78.7
65.8
56.5
49.5

5

0.2

65.8

7.5

0.2

56.5

10

0.2

49.5

5

0.2

65.8

7.5

0.2

56.5

10

0.2

49.5

5
7.5
10
3.2
5
7.5

0.2
0.2
0.2
0.2
0.2
0.2

65.8
56.5
49.5
74.6
65.8
56.5

All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (300 g).

4.1.3 Dissolution Testing
Dissolution of ITZ nanocomposites was performed using a Distek 2100C dissolution tester
(North Brunswick, NJ, USA) according to the USP II paddle method (Bilgili et al., 2018).
The dissolution medium was 1000 mL 3.0 g/L SDS solution to follow the same media as
was used within redispersion testing. The medium was maintained at 37 °C and stirred by
a paddle at 50 rpm. Nanocomposites, equivalent to a dose of 20 mg of ITZ, were added to
the medium, and 4 mL samples were taken manually at 1, 2, 5, 10, 20, 30, and 60 min. The
nanocomposite weight was determined by the theoretical drug content for each
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formulation. The absorbance of ITZ dissolved in the media was measured via UVspectroscopy (Agilent, Santa Clara, CA, USA) at 260 nm wavelength. Aliquots of the
samples were filtered using a 0.1 µm PVDF membrane type syringe filter to avoid any
effect of undissolved drug during UV-spectroscopy. The medium solution without drug
was used as the blank. The amount of drug dissolved was measured using a calibration
curve generated in (Bilgili et al., 2018), with an R2 = 0.9995. ITZ release was reported as
a function of dissolution time for an average of six replicates. >80% drug release in 20
minutes was the criteria for immediate drug release (A. Bhakay et al., 2014; Bilgili et al.,
2018). Dissolution profiles of all nanocomposites were statistically compared using
difference (ƒ1) and similarity (ƒ2) factors (Kassaye & Genete, 2013). ƒ1 values up to 15 (0‒
15) and ƒ2 values greater than 50 (50‒100) suggest statistical similarity of two profiles
(Bilgili et al., 2018).
4.1.4 Particle Size of Redispersed Nanocomposites
Particle size distribution (PSD) of all suspensions was measured by Mastersizer 3000 laser
diffraction particle size analyzer with Hydro MV cell (Malvern, United Kingdom) using
red and blue light and a detection range of 0.01 µm to 3,500 µm. Dispersant cell set at a
stir rate of 1,500 rpm, and sonication performed for 30 sec at 60% intensity. Mie scattering
theory was used to compute the volume-based distribution with a refractive index of 1.68
for ITZ and 1.33 for deionized water (Bilgili et al., 2018). An alignment of the system
followed by a background measurement of 10 sec for red and 10 sec for blue light was
taken before each set of readings. Three measurements averaged were taken and reported.
Method used was set around repeatable results from measurement to measurement on
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various samples following ISO model within the Malvern Software. During measurement,
the sample was added until obscuration fell between the ranges of 3 to 8%.

4.2 Results and Discussion
4.2.1 Nanoparticle Recovery via Redispersion
The redispersion particle size distribution from initial nanoparticle recovery can be shown
in Table 4.2. The resulting data was obtained from preliminary testing of generating
nanocomposite by scrapping off a round bottom flask. This was where a particle size
discrepancy was first noticed when a single sample produced in the rotary evaporator could
not be reproduced from one run to another. As one can see between the two sets of runs at
different polymer loadings, an issue with reproducing a result in redispersion was seen.
The issue tracing back to the particle size as discussed in Chapter 3 and can also be seen
within the D50 and D90 of the dispersed composites.

Table 4.2 Nanocomposite Redispersion: Preliminary Testing of Rotary Evaporated
Nanocomposites
Redispersed Particle Sizeb
Formulationa
D50±SD (µm)

D90±SD (µm)

Q (1µm)±SD (%)

2.5%HPC-SL

21.2±1.14

219.0±38.73

0.05±0.03

2.5%HPC-SL

17.87±3.22

235.5±64.78

1.06±0.04

10%HPC-SL

36.18±1.76

226.5±11.77

3.56±0.08

10%HPC-SL

0.16±0.01

8.11±8.01

88.83±3.2

a

All precursor suspensions of the nanocomposites have 10% ITZ and 0.2% SDS. %w/w is with respect to the
weight of deionized water (300 g).
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b

Redispersed particle size was measured at the end of a 30 min run following the procedures outlined in this
chapter.

Following the results in Table 4.2, the implementation of a 5 min mortar and pestle
step developed in Chapter 3 was used with all samples. This allowed for reproducible runs
during the redispersion testing and homogenized all following samples used throughout the
rest of the study. Continuing with mortar and pestle samples and running through a few
formulations demonstrated there was an issue with nanoparticle recovery that was not
captured in previous runs. Although increasing the polymer concentration up to a total of
7.5% HPC-SL was beneficial in the recovery of almost 25% more nanoparticles (Table
4.3), this was still a low recovery of ITZ nanoparticles as previous studies have reported
with just 2.5% HPC-SL a nanoparticle recovery close to 90% (Bilgili et al., 2018).

Table 4.3 Mortar and Pestle Processed Composites Redispersion
Redispersed Particle Sizeb

Nanocomposite Particle Size
Formulationa

Q
D50±SD

D90±SD

D50±SD

D90±SD

(µm)

(µm)

(µm)

(µm)

(1µm)±SD
(%)
2.5%HPC-SL

91.3±4.7

238±16.3

20.9±8.79

205±78.2

0.78±0.22

5%HPC-SL

75.6±1.09

185±5.20

19.3±0.76

74.5±2.66

16.4±1.54

7.5%HPC-SL

134±7.47

382±4.99

17.5±3.15

77.7±10.7

25.0±4.05

a

All precursor suspensions of the nanocomposites have 10% ITZ and 0.2% SDS. %w/w is with respect to the
weight of deionized water (300 g).
b
Redispersed particle size was measured at the end of a 30 min run following the procedures outlined in this
chapter.

With the issue of reproduceable runs resolved, we can transition to investigating
issues with polymer solubility. As mentioned in Chapter 3, the solubility of HPC was
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challenged at the increased temperature that the composites were initially being produced
at. After this processing change the following formulations were explored by redispersion
as a comparison to the initial runs. We can see from the initial results in nanoparticle
dispersion that this change was very impactful and necessary to the process of generating
true nanocomposites (Table 4.4). In addition, the particle size of the generated
nanocomposites was not very different between the feed and bleed approach compared to
the distillation method. Hence there does not appear to be a nanocomposite particle size
effect on the redispersion of nanoparticles from the nanocomposites on this set of data.

Table 4.4 Feed and Bleed Nanocomposite Redispersion
Redispersed Particle Sizeb

Nanocomposite Particle Size
Formulation

a

Q
D50±SD

D90±SD

D50±SD

D90±SD
(1µm)±SD

(µm)

(µm)

(µm)

(µm)
(%)

2.5%HPC-SL

66.5±4.7

187±18.6

5.62±0.67

31.98±1.03

22.91±3.01

5%HPC-SL

222±22.8

608±73.2

0.367±0.00

26.48±1.15

65.99±0.44

7.5%HPC-SL

122±4.1

329±8.2

0.326±0.01

15.32±0.8

68.36±1.34

a

All precursor suspensions of the nanocomposites have 10% ITZ and 0.2% SDS. %w/w is with respect to the
weight of deionized water (300 g).
b
Redispersed particle size was measured at the end of a 30 min run following the procedures outlined in this
chapter.

Continuing with the investigation of polymer impact and loading, in Table 4.5, we can
observe the impact that various polymers, at varying loadings, had on the dispersion of
nanoparticles.
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Table 4.5 Impact of Polymer Type and Loading on Redispersed Particle Size
Redispersed Particle Sizeb

Nanocomposite Particle Size
Formulation

a

Q
D50±SD

D90±SD

D50±SD

D90±SD
(1µm)±SD

(µm)

(µm)

(µm)

(µm)
(%)

2.5%HPC-SL

66.5± 4.7

187±18.6

5.62±0.67

32±1.03

22.9±3.01

5%HPC-SL

222±22.8

608±73.2

0.367±0.00

26.5±1.15

66±0.44

7.5%HPC-SL

122±4.1

329±8.2

0.326±0.01

15.32±0.80

68.4±1.34

10%HPC-SL

288±57.2

680±49.0

0.238±0.01

6.54±0.51

85.92±0.35

122±6.5

356±9.4

0.474±0.06

19.07±1.39

58.11±3.15

110±12.9

354±30.2

0.374±0.02

15.27±0.84

63.24±1.84

109±2.9

395±9.9

0.323±0.00

14.90±0.45

69.89±0.42

127±5.7

350±3.7

0.812±0.15

17.87±1.34

51.88±1.72

157±10.6

387±30.2

0.386±0.01

6.31±0.73

74.35±1.53

133±10.5

417±30.6

0.306±0.00

4.33±0.05

81.66±0.14

100±14.1

302±20.6

2.58±0.09

23.30±4.06

43.05±0.94

2.5%HPC-SL/
2.5%PVP K30
2.5%HPC-SL/
5%PVP K30
2.5%HPC-SL/
7.5%PVP K30
2.5%HPC-SL/
2.5%PEG 3350
2.5%HPC-SL/
5%PEG 3350
2.5%HPC-SL/
7.5%PEG 3350
2.5%HPC-SL/
2.5%VA 64
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2.5%HPC-SL/
134±6.6

339±24.9

2.637±0.16

21.10±2.21

40.62±1.52

87.5±3.0

305±7.9

3.06±0.04

15.73±0.63

33.42±0.50

62.0±8.9

214±28.7

0.259±0.00

4.74±0.13

83.16±0.43

136±9.0

376±5.7

0.141±0.00

0.394±0.02

98.76±0.54

108±10.4

341±21.7

0.145±0.00

0.393±0.01

98.48±0.07

5%VA 64
2.5%HPC-SL/
7.5%VA 64
2.5%HPC-SL/
0.7%F-127
2.5%HPC-SL/
2.5%F-127
2.5%HPC-SL/
5%F-127
a

All precursor suspensions of the nanocomposites have 10% ITZ and 0.2% SDS. %w/w is with respect to the
weight of deionized water (300 g).
b
Redispersed particle size was measured at the end of a 30 min run following the procedures outlined in this
chapter.

At first glance, one can see a well-defined correlation of nanoparticle release as the
polymer concentration increased for almost all formulations aside from that of VA 64. With
VA 64 a plateau of nanoparticle recovery can be seen in which the addition of more VA
64 to the formulation had a hinderance effect on the release of ITZ nanoparticles from the
composites. This could be due to the affinity of VA 64 to the ITZ nanoparticles over that
of dissolving in water, which would preferentially hinder nanoparticle release as a particle
size effect influence could not be seen with this polymer. On the other hand, at a total
polymer concentration of 10%, formulations were able to release between ~69 and 86% of
nanoparticles as compared to that of ~23% nanoparticle recovery from the baseline
formulation of 10%ITZ–2.5HPC-SL–0.2%SDS. Most notably was that of PEG containing
formulations, PEG 3350 and F-127, which not only generated a nanocomposite which
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dispersed well, but also contained very desirable processing enhancement due to the waxy
nature of PEG. As seen below in Figure 4.2 the final scraped round bottom from that of
composites containing PEG compared to that of other polymers was very evident in the
clarity of the flask.

Figure 4.2 Round bottom flasks at the end of scraping. Higher clarity correlated to an
easily processed and recovered nanocomposite. Flask on the left formulation with
additional 5%VA 64 and flask on the right containing additional 2.5%F-127 a PEG
containing triblock copolymer.
A cursory look at F-127 redispersion data in Table 4.5 suggests that the additional
2.5% F-127 was the only additional dispersant that resulted in a Q (1 µm) above 90%.
Furthermore, with additional 0.7% F-127, the formulation containing Pluronic was able to
obtain a dispersion comparable to that of other polymers which needed 7.5% additional
dispersant (Alexandridis et al., 1994). This drastic reduction in the use of additional
dispersant is very desirable in final formulations which allows a higher % drug loading
(drug payload) in the nanocomposites. F-127 is very desirable in the formation of
nanocomposites, having the characteristics of PEG to be processed very efficiently and
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enhancing the wettability of the nanocomposites during the redispersion owing to its
surfactant-like properties.
4.2.2 Dissolution Enhancement of ITZ
Figure 4.3 presents the dissolution profiles of as-received ITZ (unprocessed ITZ) powder,
a nanocomposite powder prepared via rotary drying of the 2.5%HPC-SL–2.5%F-127–
0.2% nanosuspension, a microparticle composite (labeled “Unmilled”) prepared with the
same formulation but using unmilled ITZ suspension, a physical mixture (PM) of asreceived ITZ with the formulation but prepared via simple blending, and spray-dried
nanocomposite of 10%ITZ–2.5%HPC-SL–0.2%SDS nanosuspension prepared by Bilgili
et al. (2018). The as-received ITZ particles dissolved extremely slowly due to its low
solubility and their large particle sizes (D50 =15.5 µm and D90 = 45.8 µm) perhaps presence
of aggregates; only 8% of the drug dissolved after 60 min. Presence of the hydrophilic
dispersants in a PM had a slight, but almost negligible effect, whereas rotary evaporation
of a suspension of the unmilled ITZ with the dispersants (Unmilled) led to a nanocomposite
with a more notable increase in drug release (22% at 60 min) due to more intimate contact
of the dispersants with ITZ particles. These results suggest that without some alteration of
ITZ particle size or solid state of the crystals, it is impossible to achieve immediate ITZ
release (80% release within 20 min).

48

100
90

% Drug Dissolved

80
70
60
50
40
30
20
10
0
0

10

20

30

40

50

60

70

Time (min)
as-recei ved ITZ

PM

Un-mi lled

2.5% F-127 (136.4μm)

Spray Dried Baseline (11.3μm)

Figure 4.3 ITZ dissolution from nanocomposites compared to physical mixture and rotary
evaporated suspension without milling. All formulations are based on having 10%ITZ–
2.5%HPC-SL–2.5%F-127–0.2%SDS aside from as-received ITZ and spray-dried
nanocomposite which only has 10%ITZ–2.5%HPC-SL–0.2%SDS. PM is a physical
mixture. Un-milled was rotary evaporated without milling. Nano-milled was milled and
dried on the rotary evaporator. Spray-dried nanocomposite and as-received ITZ data were
obtained from (Bilgili et al., 2018).
The 10%ITZ–2.5%HPC-SL–0.2%SDS suspension was wet-milled, 2.5% F-127
was dissolved in it, and the resulting nanosuspension was dried by the rotary evaporator
(Figure 4.3). This nanocomposite (2.5%F-127) achieved immediate release. XRPD and
DSC studies on nanomilled ITZ (Bilgili et al., 2018) have established that ITZ was largely
nanocrystalline. Hence, the observed remarkable increase in the dissolution rate as
compared with “PM” and “Unmilled” samples is simply due to the large surface area of
the ITZ nanoparticles in the nanocomposites. These nanoparticles were present in the
precursor nanosuspension (refer to Table 2.2): D50 = 0.132 µm and D90 = 0.325 µm. These
ITZ nanoparticles has about 117 times larger external surface area than the as-received,
unprocessed ITZ particles. Thus, the profiles in Figure 4.3 signify that wet stirred media
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milling is the most important processing step that enhances the ITZ dissolution. The
calculated difference factor f1 and the similarity factor f2 in Table 4.6 suggest that effect of
processing with ITZ nanoparticles is statistically different and has the largest impact in
comparison to only processing on the rotary evaporator (Table 4.6). A spray-dried
nanocomposite even with less dispersant (prepared using a nanosuspension of 10%ITZ–
2.5%HPC-SL–0.2%SDS) outperformed all other samples, achieving immediate release
within 5 min. The difference between spray-drying and rotary drying will be further
scrutinized in Section 4.2.3.

Table 4.6 f1 and f2 Statistics for the Dissolution Profiles of Differently Processed ITZ
Particles
Processing Condition/Formulation
Un-milled Rotary
Physical Mixture
As Received ITZa

Evaporated Suspension
10%ITZ 2.5%HPC-SL
10%ITZ 2.5%HPC-SL
2.5%F-127 0.2%SDS
2.5%F-127 0.2%SDS

f1b

95.68

94.60

82.22

f2b

12.06

12.34

15.27

a

Dissolution data to calculate statistics was obtained from (Bilgili et al., 2018).
The dissolution profiles were compared to 10%ITZ–2.5%HPC-SL–2.5%F-127–0.2%SDS nanocomposite
which was taken as the reference profile.
b

Let us examine the effects of various polymers on the dissolution performance (see
Figure 4.4). Most formulations with the additional 2.5% dispersant as compared to the
baseline nanocomposite (10%ITZ–2.5%HPC-SL–0.2%SDS) were able to achieve an 80%
dissolution within a 20 min time. The dissolution profiles of all rotary dried
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nanosuspensions are somewhat constrained within a narrow space, except the baseline
nanocomposite and the “low” dissolution profile of the 2.5% HPC-SL nanocomposite (with
D50 = 222.4 µm particles). The latter nanocomposite had much larger D50 than all other
nanocomposites; hence, its dissolution took longer despite the presence of additional 2.5%
HPC-SL (total of 5% HPC-SL), which clearly demonstrates the importance of
nanocomposite particle size besides the itraconazole (drug) particle size. A slight
improvement was also observed when 2.5%F-127 nanocomposite nanoparticles (D50 =
136.4 µm) was milled in Labram equipment after mortar and pestle milling into the 2.5%F127 nanocomposite (D50 = 28.4 µm). Finally, the superfast dissolution from the spray-dried
nanocomposite particles with D50 = 11.3 µm (highest profile in Figure 4.4) also validates
the positive impact of finer nanocomposite particles on drug release. Unfortunately, for the
other nanocomposites, this nanocomposite particle size effect is a confounding factor along
with the different polymers used.
In Table 4.7, the f1 and f2 statistics show that there is not a significant difference
between the different formulations aside from that of 2.5%HPC-SL which does appear to
show a slight dissimilarity from the baseline in its poor performance in the dissolution
testing.
The f1 and f2 statistics from the nanocomposite milled formulation which underwent
50 min of ball milling and contained 2.5% F-127 additional over baseline showed no
difference, see Table 4.8, from taking the particle size of 136.4 µm D50 down to 28.44 µm
D50 particle size. On the other hand, there was a statistical difference in the dissolution
performance of the spray dried nanocomposite from Bilgili et al. (2018), compared to the
same formulation that was rotary evaporated having an f1 of 21.84 and f2 of 35.62, showing
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there is a significant improvement in the dissolution potentially due to the particle size
difference in the nanocomposites (Bilgili et al., 2018).

100
90
80

% Drug Dissolved

70
60
50
40
30
2.5% F-127 (136.4μm)

2.5% F-127 Composite Milled (28.44μm)

20

Baseline (66.5μm)

2.5% HPC-SL (222.4μm)

10

2.5% VA 64 (100.4μm)

2.5% PEG 3350 (127.4μm)

2.5 % PVP K30 (122.3μm)

Spray Dried Baseline (11.3μm)

0
0

10

20

30

40

50

60

70

Time (min)

Figure 4.4 Dissolution at 2.5% additional dispersant over baseline formulation 10%ITZ
2.5%HPC-SL 0.2%SDS. Nanocomposite particle size for reference is recorded next to each
formulation in the legend. Spray-dried nanocomposite data were taken from (Bilgili et al.,
2018). The formulation of the spray-dried nanocomposite was that of the baseline
formulation 10%ITZ 2.5%HPC-SL 0.2%SDS.
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Table 4.7 f1 and f2 Statistics for Polymer Type
Processing Condition/Formulationa
2.5% F2.5%

127

2.5%

2.5%

2.5%

2.5%

F-127b

Composite

HPC-SLb

VA 64b

PEG 3350b

PVP K30b

Milledb
f1c

6.24

12.6

14.5

11.3

6.25

6.52

f2c

70.8

57.4

49.2

58.5

72.1

69.6

a

All nanocomposites have 10% ITZ 2.5%HPC-SL 0.2% SDS (baseline). Additional dispersants were shows
in the table%w/w is with respect to the weight of deionized water (300 g).
b
Each formulation composition is that of additional dispersant added in addition to baseline nanocomposite.
c
The dissolution profiles were compared to 10%ITZ–2.5%HPC-SL–0.2%SDS nanocomposite which was
taken as the reference profile.

4.2.3 Spray Drying vs. Rotary Evaporator Drying
The dissolution performance of rotary evaporated nanocomposites and that of spray-dried
nanocomposites was compared in Figure 4.5. The initial impression that can be seen from
the figure is a slight increase in the dissolution performance as an additional 2.5% of F-127
was added to the formulation. In addition to the polymer effect, the particle size of the
nanocomposites was of great interest due to the variety that can be seen in Table 3.3. The
smaller nanocomposites in theory would have higher surface area and assist with the
dissolution and redispersion performance. As one can see from the dissolution results
below looking at the reduction of particle size, we can see that there is a slight assistance
from having a smaller nanocomposite particle size. To quantify the statistical significance
of these differences, f1 and f2 factors were calculated on the formulations in Figure 4.5 (see
Table 4.8).
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Figure 4.5 Dissolution comparison of spray-dried vs. rotary evaporated nanocomposites.
Nanocomposite particle size for reference is recorded next to each formulation in the
legend. Spray-dried nanocomposite data were taken from (Bilgili et al., 2018). The
formulation of the spray-dried nanocomposite was that of the baseline formulation 10%ITZ
2.5%HPC-SL 0.2%SDS and other contained an additional 2.5% of their respective
dispersant.
The f1 and f2 statistics for all formulations compared to the spray dried were
statistically different based on the values reported within Table 4.8. A particle size effect
from the spray dried nanocomposites being the smallest could be the driving factor in the
significant improvement which spray dried composites have over that of rotary evaporated
composites. In addition, the effect of milling the 2.5% F-127 sample from a particle size
of 136.4 µm down to 28.44 µm was not statistically different as evident in the f1 and f2
values in Table 4.8.
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Table 4.8 f1 and f2 Statistics for Dissolution of Rotary Evaporated and Spray-Dried
Nanocomposites
Processing Condition/Formulationa
2.5%
Baseline

Spray-Dried Baseline
F-127 Composite Milled

b

f1c

5.97

7.82

38.0

f2c

70.8

65.6

31.0

a

All nanocomposites have 10% ITZ 2.5%HPC-SL 0.2% SDS. %w/w is with respect to the weight of
deionized water (300 g).
b
Each formulation composition is that of additional dispersant added in addition to baseline nanocomposite.
c
The dissolution profiles were compared to 10%ITZ–2.5%HPC-SL–2.5%F-127–0.2%SDS nanocomposite
which was taken as the reference profile.

To conclude, the particle size effect from the rotary evaporated nanocomposites at
28.44 µm down to 11.3 µm of the spray-dried nanocomposites was a statistical and visual
improvement into the dissolution performance of the composites. On the other hand, the
particle size reduction from that of the same two rotary evaporated nanocomposites from
136.4 µm down to 28.44 µm was not statistically different and did not show a great
improvement in the dissolution. This suggests that there may be a sweet spot in the
nanocomposite particle size that will allow for great improvement in dissolution without
compromising powder properties (e.g. deteriorated flowability) associated with particles
sizes below a D50 of 50 µm.
Interestingly, the impact of polymer type/loading on the nanocomposite
redispersion was notable and significant; however, their impact on the dissolution was
somewhat less remarkable. To put it another way, our dissolution test protocol has less
discriminatory power than the dissolution test. This could be due to the use of 3 g/L SDS
concentration as opposed to a 0.1 N HCl redispersion/dissolution media, which could have
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improved the discriminatory power of the dissolution testing. Also, there was no significant
correlation between the redispersion test and the dissolution test. In general, a significant
correlation between these two different tests is not expected as they measure fundamentally
different, but interconnected phenomena. The hydrodynamics in the redispersion vessel
and the dissolution vessel are different. The large volume of aqueous media allows for
dissolution of the drug particles, thus facilitating redispersion; whereas drug cannot
dissolve in the redispersion test. In other words, the redispersion during the dissolution test
is expected to be faster than that in the redispersion test. Interestingly, for the fluidized-bed
coated/dried nanocomposites of griseofulvin (another BCS Class II drug), Bhakay et al.
(2018a) established a correlation between the redispersion test and the dissolution test
(Bhakay, Davé, et al., 2018). Nevertheless, they used deionized water as the medium in
both tests, which enabled excellent discrimination power for different formulations. We
could not use water here as ITZ solubility would be undetectable by UV spectroscopy.

4.3 Conclusions
The redispersion and dissolution data presented in this manuscript has shown great insight
into nanocomposites and their performance when dried using a rotary evaporator. The
dissolution data showed that wet stirred media milling was required to achieve a significant
increase in ITZ release rate. In general, with respect to the effect of different polymers on
the dissolution performance, there was no statistical difference among all formulated
nanocomposites provided they do not have a median size above ~150 µm. On the other
hand, the redispersion tests told a different story. Across the same polymer concentration,
each polymer affected the dispersion of nanoparticles from the nanocomposite affecting
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the percentage of nanoparticles that were able to be recovered within the testing period.
Out of all formulations in this test, the samples containing F-127 had the most significant
impact on the reconstitution of nanoparticles achieving complete dispersion with just 2.5%
additional dispersant. This was the only formulation to completely disperse
nanocomposites back to a nanoparticle suspension. At just 0.7% additional F-127, the
polymer was able to disperse an equivalent percentage compared to that of other
formulations containing 7.5% additional polymer in the formulation. This drastic
difference in use of polymer makes for a large difference in the overall assay of the
nanocomposites that is beneficial when looking at downstream tablet formulation.
However, both tests agreed on the fact that additional 2.5% dispersant led to higher extent
of nanoparticle recovery and faster dissolution; however, the dissolution tests were less
discerning than the redispersion tests.
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CHAPTER 5
CONCLUSION AND FUTURE WORK

5.1 Conclusions
This research has established the feasibility of rotary evaporation drying of wet-milled
itraconazole nanosuspensions and examined the impact of various polymers/surfactants on
the redispersion and drug release from the nanocomposites. Overall, rotary evaporation of
drug nanosuspensions could yield drug nanocomposites with high drug loading (~67%),
fast redispersion, and immediate release of poorly soluble drugs, with less concern over
potential flowability issues than spray-dried nanocomposites.
Wet stirred media milling plays the most important role in enhancing the drug
dissolution as it increased the drug surface area by ~100-folds. The presence of hydrophilic
water-soluble polymers helped to enhance the wettability and enabled film formation
during the nanocomposite formation. The neutral polymeric surfactant (Pluronic F-127)
and the anionic surfactant (SDS) also helped to improve the wettability of the
nanocomposites; while SDS also contributed to the physical stability of the precursor
suspensions. The impact of various polymers was more apparent in the redispersion tests
than in the dissolution tests due to the lower discrimination power of the latter. Provided
that the nanocomposites had a median size less than ~150 µm, the nanocomposites with
1:2 dispersant:polymer ratio enabled immediate ITZ release from the nanocomposites
during the in vitro dissolution tests.
In rotary evaporation drying, a feed and bleed approach proved to be the best
method of generating nanocomposites when studying the redispersion of nanoparticles
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from certain formulations. Mortar and pestle milling of the dried nanocomposite particles
enabled us to produce a relatively homogeneous powder with all particles less than 1 mm
and reduced standard deviation in measured particle sizes. In larger scales, mortar and
pestle milling could be replaced by continuous conical-screen milling. Besides reducing
the particle size range, mortar and pestle milling reduced the particle sizes, thus enabling
faster redispersion and dissolution.
While the spray-drying led to finer nanocomposites with the median sizes (10–30
µm) with faster drug release, such small particles are associated with poor flowability. The
nanocomposites prepared via rotary evaporator drying followed by mortar and pestle
milling have coarser particles (median size ranging from ~50–150 µm), which are expected
to have more favorable flowability. Therefore, when optimized, the wet stirred media
milling followed by rotary evaporation and a size-determining milling step could help
formulators to design ideal nanocomposites for effective delivery of poorly soluble drugs.

5.2 Future Work
5.2.1 Use of Other Dispersants for Dissolution Enhancement
Some categories of dispersants and their potential effect on redispersion and dissolution
were not considered in this work. The need for dispersant optimization using colloidal
superdisintegrants

(a

novel

dispersant),

sugars,

sugar

alcohols,

and

other

polymers/surfactants is obvious. The optimization of these various dispersant would take
a variety of experiments to understand the complete impact of these dispersants on the
formulations generated from rotary evaporation.
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5.2.2 Flowability and Tabletability Assessment of Nanocomposites
The nanocomposite powders are ultimately integrated into various solid oral dosages such
as oral capsules and tablets for final consumption and use by the patient. To create tablets,
flowability, compactability, and compressibility characteristics of the nanocomposites
either directly or after addition of excipients such as functional fillers and lubricants. The
use of an FT-4 to measure the resistance of a powder to flow and the stress on a
nanocomposite would better help to understand what powder properties are desired for
tableting. In addition, the use of bulk and tapped density would also show which
formulations are more desirable as powders that have the least difference in bulk and tapped
density tend to tablet much better without the need for additional dispersants to bulk up the
tablet for desirable properties.
5.2.3 Pharmacokinetics Studies
In this study, we were able to demonstrate a sensitive method of characterizing
nanocomposites dried with a rotary evaporator using redispersion. In addition, the use of
dissolution was also studied with less discrimination between the different formulations.
To understand the full impact on polymers on these nanocomposites, the use of
pharmacokinetic studies would need to be conducted to see if the differences in redispersed
nanoparticles will translate into greater systemic absorption by the body by having a
constant reservoir of nanoparticles that can dissolve as the body is absorbing the drug.
These studies should be able to show if the results from in vitro redispersion or dissolution
are translated into absorption or if the results seen in the dissolution test hold true and no
difference is seen between the formulations regardless of the polymers used to generate
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nanocomposites. Therefore, pharmacokinetic studies are essential to understand the full
extent of differences in formulating nanocomposites produced from rotary evaporation.
5.2.4 Thin Film Evaporation (TFE): Drying of Nanosuspensions
A rotary evaporation technique was developed in this study for lab scale understanding of
drying nanocomposites. This lab scale unit is meant to be analogous representation of the
TFE and the properties of nanocomposites that can be dried using this technique. To
completely understand if the rotary evaporator was a correct choice for the lab scale
performance of drying drug nanosuspensions, running scale up runs on the TFE and
comparing the dried nanocomposites using the same gauntlet of tests, redispersion and
dissolution, to that of rotary evaporated nanocomposites is a must to close the gap in this
understanding of nanocomposite formation. This would be done for a similar set of
formulations as was used in the dissolution testing to understand the particle size, polymer
type, and overall characteristics of both TFE nanocomposites and those produced from
rotary evaporation.
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